ArticleACS omega2025
Sustainable Graphene Synthesis and Analysis of Graphene-Based PLA Nanocomposites: Impacts of Polymer Functionalization and Potential Applications in Cancer Treatments.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Due to their optimized mechanical, physicochemical, and biocompatible properties, poly-(lactic acid) (PLA)-based composites functionalized with graphene have attracted growing interest in the biomedical field. In this study, a nanocomposite was developed by incorporating graphene at different concentrations into a commercial PLA-like resin, processed using the additive manufacturing technique of vat photopolymerization. Cell viability assays using human melanoma (MV3) tumor cells were performed on samples containing 0.1 and 0.3 wt % graphene. The results showed a significant, concentration-dependent inhibition of tumor cell proliferation. In contrast, nontumor cells (MNP-01 and MRC-5) exhibited good biocompatibility with the material, reinforcing the selective behavior of the composite. To better understand the composite's anticancer potential and its interactions with cells, extensive structural, topographical, and vibrational characterizations were conducted. X-ray diffraction (XRD) analysis confirmed that the addition of graphene did not significantly alter the polymer's structural profile. Raman spectroscopy yielded similar findings, showing unchanged vibrational modes. Atomic force microscopy (AFM) revealed changes in surface roughness, while Vickers microhardness (VM) tests showed increased hardness with higher graphene content. Wettability tests supported the biological findings, indicating increased hydrophilicity with higher graphene concentrations, which correlates with decreased MV3 cell viability. These results help elucidate the mechanisms mediating the interaction between cells and the PLA/graphene composite surface.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.